Microbix Biosystems Inc. (MBXBF)
USD 0.26
(1.69%)
USD 0.26
(1.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.73 Million CAD | -201.63% |
| 2022 | 2.69 Million CAD | -44.33% |
| 2021 | 4.83 Million CAD | 1021.96% |
| 2020 | -524.6 Thousand CAD | -147.27% |
| 2019 | 1.1 Million CAD | 249.4% |
| 2018 | -742.8 Thousand CAD | 50.46% |
| 2017 | -1.49 Million CAD | -1110.42% |
| 2016 | 148.4 Thousand CAD | -57.47% |
| 2015 | 348.98 Thousand CAD | -26.63% |
| 2014 | 475.62 Thousand CAD | 182.81% |
| 2013 | 168.17 Thousand CAD | 110.67% |
| 2012 | -1.57 Million CAD | 3.95% |
| 2011 | -1.64 Million CAD | 0.58% |
| 2010 | -1.65 Million CAD | 4.28% |
| 2009 | -1.72 Million CAD | 50.59% |
| 2008 | -3.49 Million CAD | -49.07% |
| 2007 | -2.34 Million CAD | -22.07% |
| 2006 | -1.91 Million CAD | -1370.02% |
| 2005 | 151.01 Thousand CAD | 385.23% |
| 2004 | -52.94 Thousand CAD | 87.58% |
| 2003 | -426.33 Thousand CAD | -500.91% |
| 2002 | 106.34 Thousand CAD | -66.05% |
| 2001 | 313.18 Thousand CAD | 179.56% |
| 2000 | -393.65 Thousand CAD | 91.44% |
| 1999 | -4.6 Million CAD | -130.0% |
| 1998 | -2 Million CAD | -1900.0% |
| 1997 | -100 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 165.31 Thousand CAD | -63.99% |
| 2024 Q1 | 2.56 Million CAD | 15.64% |
| 2024 Q2 | 459.06 Thousand CAD | -82.14% |
| 2023 Q2 | 232.98 Thousand CAD | 121.1% |
| 2023 FY | -2.73 Million CAD | -201.63% |
| 2023 Q4 | 2.22 Million CAD | 503.29% |
| 2023 Q3 | -551.03 Thousand CAD | -336.51% |
| 2023 Q1 | -1.1 Million CAD | -456.61% |
| 2022 Q3 | 832.73 Thousand CAD | -11.09% |
| 2022 Q4 | -198.39 Thousand CAD | -123.82% |
| 2022 FY | 2.69 Million CAD | -44.33% |
| 2022 Q1 | 1.12 Million CAD | -29.04% |
| 2022 Q2 | 936.61 Thousand CAD | -16.49% |
| 2021 Q3 | 1.78 Million CAD | 66.69% |
| 2021 FY | 4.83 Million CAD | 1021.96% |
| 2021 Q1 | 393.22 Thousand CAD | 112.44% |
| 2021 Q2 | 1.07 Million CAD | 172.99% |
| 2021 Q4 | 1.58 Million CAD | -11.67% |
| 2020 Q3 | -440.23 Thousand CAD | -100.99% |
| 2020 Q2 | -219.03 Thousand CAD | 62.58% |
| 2020 FY | -524.6 Thousand CAD | -147.27% |
| 2020 Q4 | -3.16 Million CAD | -617.96% |
| 2020 Q1 | -585.26 Thousand CAD | -358.18% |
| 2019 Q1 | -119.29 Thousand CAD | 61.16% |
| 2019 Q4 | -127.73 Thousand CAD | 33.23% |
| 2019 Q3 | -191.32 Thousand CAD | -139.69% |
| 2019 Q2 | 482.03 Thousand CAD | 504.07% |
| 2019 FY | 1.1 Million CAD | 249.4% |
| 2018 Q4 | -307.13 Thousand CAD | -32160.13% |
| 2018 Q2 | -342.5 Thousand CAD | -263.87% |
| 2018 FY | -742.8 Thousand CAD | 50.46% |
| 2018 Q1 | -94.12 Thousand CAD | 89.74% |
| 2018 Q3 | 958.00 CAD | 100.28% |
| 2017 Q4 | -917.67 Thousand CAD | -459.2% |
| 2017 FY | -1.49 Million CAD | -1110.42% |
| 2017 Q3 | -164.1 Thousand CAD | -252.44% |
| 2017 Q2 | 107.64 Thousand CAD | 120.49% |
| 2017 Q1 | -525.4 Thousand CAD | -194.51% |
| 2016 Q2 | 161.97 Thousand CAD | 137.81% |
| 2016 FY | 148.4 Thousand CAD | -57.47% |
| 2016 Q1 | -428.42 Thousand CAD | -1861.09% |
| 2016 Q3 | -141.08 Thousand CAD | -187.1% |
| 2016 Q4 | 555.93 Thousand CAD | 494.05% |
| 2015 Q3 | 147.76 Thousand CAD | 71.16% |
| 2015 FY | 348.98 Thousand CAD | -26.63% |
| 2015 Q2 | 86.33 Thousand CAD | -4.66% |
| 2015 Q1 | 90.55 Thousand CAD | 129.89% |
| 2015 Q4 | 24.32 Thousand CAD | -83.54% |
| 2014 Q4 | -302.96 Thousand CAD | -202.85% |
| 2014 Q3 | 294.56 Thousand CAD | 9.25% |
| 2014 Q1 | 214.4 Thousand CAD | -71.85% |
| 2014 Q2 | 269.62 Thousand CAD | 25.75% |
| 2014 FY | 475.62 Thousand CAD | 182.81% |
| 2013 FY | 168.17 Thousand CAD | 110.67% |
| 2013 Q2 | 279.67 Thousand CAD | 161.99% |
| 2013 Q1 | -451.18 Thousand CAD | -188.22% |
| 2013 Q3 | 165.48 Thousand CAD | -40.83% |
| 2013 Q4 | 761.61 Thousand CAD | 360.24% |
| 2012 Q1 | -270.65 Thousand CAD | -8.05% |
| 2012 FY | -1.57 Million CAD | 3.95% |
| 2012 Q2 | -348.73 Thousand CAD | -28.85% |
| 2012 Q4 | 511.41 Thousand CAD | 8.59% |
| 2012 Q3 | 470.94 Thousand CAD | 235.04% |
| 2011 Q3 | -498.51 Thousand CAD | -72.92% |
| 2011 Q4 | -250.47 Thousand CAD | 49.76% |
| 2011 FY | -1.64 Million CAD | 0.58% |
| 2011 Q1 | -503.93 Thousand CAD | -292.46% |
| 2011 Q2 | -288.28 Thousand CAD | 42.79% |
| 2010 Q1 | -523.09 Thousand CAD | -80.54% |
| 2010 Q3 | -1.03 Million CAD | -187.56% |
| 2010 Q2 | -358.52 Thousand CAD | 31.46% |
| 2010 FY | -1.65 Million CAD | 4.28% |
| 2010 Q4 | 261.83 Thousand CAD | 125.4% |
| 2009 Q3 | -443.11 Thousand CAD | 28.76% |
| 2009 Q4 | -289.73 Thousand CAD | 34.61% |
| 2009 FY | -1.72 Million CAD | 50.59% |
| 2009 Q2 | -621.98 Thousand CAD | -56.02% |
| 2009 Q1 | -398.64 Thousand CAD | 19.98% |
| 2008 FY | -3.49 Million CAD | -49.07% |
| 2008 Q4 | -498.19 Thousand CAD | 43.36% |
| 2008 Q1 | -935.37 Thousand CAD | -32.18% |
| 2008 Q2 | -1.23 Million CAD | -32.24% |
| 2008 Q3 | -879.65 Thousand CAD | 28.89% |
| 2007 Q4 | -707.66 Thousand CAD | 15.46% |
| 2007 FY | -2.34 Million CAD | -22.07% |
| 2007 Q3 | -837.08 Thousand CAD | -119.36% |
| 2007 Q2 | -381.59 Thousand CAD | 8.02% |
| 2007 Q1 | -414.88 Thousand CAD | 67.0% |
| 2006 FY | -1.91 Million CAD | -1370.02% |
| 2006 Q1 | -118.62 Thousand CAD | -116.45% |
| 2006 Q4 | -1.25 Million CAD | -556.84% |
| 2006 Q2 | -350.59 Thousand CAD | -195.56% |
| 2006 Q3 | -191.41 Thousand CAD | 45.4% |
| 2005 Q2 | 115.66 Thousand CAD | 252.74% |
| 2005 Q1 | 32.79 Thousand CAD | -93.19% |
| 2005 Q3 | 57.36 Thousand CAD | -50.4% |
| 2005 Q4 | -54.8 Thousand CAD | -195.53% |
| 2005 FY | 151.01 Thousand CAD | 385.23% |
| 2004 Q3 | -284.89 Thousand CAD | -267.79% |
| 2004 Q1 | -172.3 Thousand CAD | -52.3% |
| 2004 Q2 | -77.46 Thousand CAD | 55.04% |
| 2004 FY | -52.94 Thousand CAD | 87.58% |
| 2004 Q4 | 481.72 Thousand CAD | 269.08% |
| 2003 Q3 | -88.57 Thousand CAD | -37.02% |
| 2003 Q2 | -64.64 Thousand CAD | 59.6% |
| 2003 Q1 | -159.98 Thousand CAD | -211.44% |
| 2003 Q4 | -113.13 Thousand CAD | -27.73% |
| 2003 FY | -426.33 Thousand CAD | -500.91% |
| 2002 Q3 | 89.65 Thousand CAD | 88.09% |
| 2002 FY | 106.34 Thousand CAD | -66.05% |
| 2002 Q2 | 47.66 Thousand CAD | 127.31% |
| 2002 Q1 | -174.54 Thousand CAD | -1344.23% |
| 2002 Q4 | 143.56 Thousand CAD | 60.13% |
| 2001 Q2 | 118.63 Thousand CAD | 11.6% |
| 2001 Q4 | 14.02 Thousand CAD | -82.04% |
| 2001 Q3 | 78.11 Thousand CAD | -34.16% |
| 2001 Q1 | 106.3 Thousand CAD | 1575.6% |
| 2001 FY | 313.18 Thousand CAD | 179.56% |
| 2000 Q4 | 6344.00 CAD | 106.34% |
| 2000 Q3 | -100 Thousand CAD | 66.67% |
| 2000 Q2 | -300 Thousand CAD | 0.0% |
| 2000 Q1 | - CAD | 100.0% |
| 2000 FY | -393.65 Thousand CAD | 91.44% |
| 1999 Q3 | -200 Thousand CAD | 66.67% |
| 1999 Q4 | -3.3 Million CAD | -1550.0% |
| 1999 Q1 | -400 Thousand CAD | -500.0% |
| 1999 Q2 | -600 Thousand CAD | -50.0% |
| 1999 FY | -4.6 Million CAD | -130.0% |
| 1998 Q1 | -700 Thousand CAD | -133.33% |
| 1998 FY | -2 Million CAD | -1900.0% |
| 1998 Q4 | 100 Thousand CAD | 133.33% |
| 1998 Q3 | -300 Thousand CAD | 72.73% |
| 1998 Q2 | -1.1 Million CAD | -57.14% |
| 1997 FY | -100 Thousand CAD | 0.0% |
| 1997 Q3 | 200 Thousand CAD | 0.0% |
| 1997 Q2 | - CAD | 0.0% |
| 1997 Q4 | -300 Thousand CAD | -250.0% |
| 1997 Q1 | - CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -117.869% |
| Skye Bioscience, Inc. | -13.67 Million USD | 79.985% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.343% |
| Nascent Biotech, Inc. | -2.22 Million USD | -22.717% |
| Qrons Inc. | -643.67 Thousand USD | -325.125% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 64.823% |
| CSL Limited | 3.7 Billion USD | 100.074% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 84.667% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 45.754% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -298.345% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.07% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -558.621% |
| Rebus Holdings, Inc. | -664 Thousand USD | -312.113% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -104.91% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -602.424% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 82.757% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.188% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 155.677% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -945.533% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.391% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 4.002% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -78.147% |
| Mesoblast Limited | -84.14 Million USD | 96.748% |
| Marizyme, Inc. | -34.08 Million USD | 91.972% |
| Genus plc | 6.4 Million USD | 142.757% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 128.088% |
| Pharming Group N.V. | -4.87 Million USD | 43.92% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -37.753% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -193.804% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 67.228% |
| ContraFect Corporation | -56.88 Million USD | 95.19% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 39.921% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -95.182% |
| IMV Inc. | -38.67 Million USD | 92.924% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 0.524% |
| MultiCell Technologies, Inc. | -722.81 USD | -378482.477% |
| ONE Bio Corp. | 13.68 Million USD | 120.001% |
| Accustem Sciences Inc. | -3.74 Million USD | 26.959% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.361% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -466.476% |
| Q BioMed Inc. | -3.44 Million USD | 20.582% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 177.3% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -4.145% |
| Biomind Labs Inc. | -1 Million USD | -171.04% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.022% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 5.681% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 58.838% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -46.775% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -9036.058% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -41.593% |
| GB Sciences, Inc. | -1.42 Million USD | -92.637% |
| Alpha Cognition Inc. | -9.7 Million USD | 71.806% |
| HST Global, Inc. | -140.9 Thousand USD | -1842.013% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -143.259% |
| Halberd Corporation | -75.05 Thousand USD | -3546.145% |
| Enzolytics Inc. | -2.14 Million USD | -27.347% |
| Agentix Corp. | -1.37 Million USD | -99.484% |
| Resverlogix Corp. | -12.74 Million USD | 78.536% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 13.63% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.356% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -162.11% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 6.269% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -73.263% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 19.634% |
| AVAX Technologies, Inc. | 6.69 Million USD | 140.886% |
| Zenith Capital Corp. | -8.94 Million USD | 69.401% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.342% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -15607.663% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -11.449% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1495.498% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -36.497% |
| Kadimastem Ltd | -3.04 Million USD | 9.993% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -178.078% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1407.801% |
| LadRx Corporation | -3.82 Million USD | 28.434% |
| Cell Source, Inc. | -4.32 Million USD | 36.735% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -298.345% |
| NovAccess Global Inc. | -2.46 Million USD | -10.932% |
| Affymax, Inc. | -15.04 Million USD | 81.813% |
| Itoco Inc. | -919.14 Thousand USD | -197.717% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 35.437% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -144.543% |
| Mobile Lads Corp. | -554.55 Thousand USD | -393.451% |
| CytoDyn Inc. | -18.05 Million USD | 84.846% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -10771.8% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1143.392% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -384.562% |
| SYBLEU INC | -149.18 Thousand USD | -1734.316% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -50.658% |
| International Stem Cell Corporation | -663 Thousand USD | -312.735% |
| Bioxytran, Inc. | -3.82 Million USD | 28.368% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5098.389% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -13353.451% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 92.455% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -69.124% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -271.881% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 12.04% |
| Neutra Corp. | -229.48 Thousand USD | -1092.418% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 84.398% |
| PureTech Health plc | -146.19 Million USD | 98.128% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 87.267% |
| IXICO plc | -1.43 Million USD | -90.427% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 71.168% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.753% |
| CSL Limited | 3.81 Billion USD | 100.072% |
| Cellectis S.A. | -108.85 Million USD | 97.486% |